Literature DB >> 6144046

Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites.

M P Martres, P Sokoloff, M Delandre, J C Schwartz, P Protais, J Costentin.   

Abstract

In order to document the hypothesis that antipsychotics may interact with more than one class of cerebral dopamine receptors, the relative potencies of a series of compounds were compared in three behavioral tests and in binding studies with two radioligands. Apomorphine (0.6 mg/kg) simultaneously elicited in rat two kinds of facial stereotypies (sniffing and licking) and a stereotyped climbing behavior, allowing to compare in the same animals the relative potencies of various antipsychotics against the three behaviors. Only some substituted benzamides (Sulpiride, LUR 2366 and DAN 2163) antagonised at significantly lower dosages climbing than sniffing (or licking). The possibility that this discriminant potency might be related to a distinct affinity for two classes of dopamine receptors was investigated by binding studies on striatal membranes with 3H-apomorphine and 3H-domperidone. From lesion and subcellular fractionation studies, two classes of binding sites both labeled with 3H-domperidone but distinguished by apomorphine i.e. D-2 sites with nM affinity and D-4 sites with microM affinity for the dopamine agonist (according to the nomenclature of Sokoloff et al. 1980 b) appear to be differently localised in striatum. Thus D-2 sites, whose number decreases after kainate lesion, are not significantly modified following cortical lesions and preferentially sediment with heavy primary subcellular fractions. In contrast D-4 sites, less affected by kainate lesions, are significantly decreased following cortical lesions (-30%) and preferentially sediment with the light subcellular fractions. In addition the apparently heterogeneous recognition of total 3H-domperidone binding sites (i.e. the sum of D-2 and D-4 sites) by dopamine and apomorphine persists in the presence of guanosine-5'-triphosphate (pseudo-Hill coefficient of 0.60 instead of 0.55). This suggests that D-2 and D-4 sites cannot be considered as two discrete states of the same receptor strictly convertible one into the other by guanylnucleotides. Whereas most dopamine antagonists inhibited D-2 and D-4 site binding with similar affinities, the three benzamide derivatives with the largest selectivity in behavioral tests displayed 2-3-fold higher affinity for D-4 than for D-2 sites and the ratios of ID50 values of the whole series of antagonists against sniffing (or licking) and climbing behaviors were correlated (P less than 0.01) with the ratios of Ki values regarding D-2 and D-4 site binding. Also, sulpiride and LUR 2366 unlike haloperidol and metoclopramide, inhibited the total specific 3H-domperidone binding in a biphasic manner.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144046     DOI: 10.1007/bf00506189

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

1.  The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation.

Authors:  E G GRAY; V P WHITTAKER
Journal:  J Anat       Date:  1962-01       Impact factor: 2.610

2.  A glutamatergic corticostriatal path?

Authors:  P L McGeer; E G McGeer; U Scherer; K Singh
Journal:  Brain Res       Date:  1977-06-10       Impact factor: 3.252

3.  [Chemistry and pharmacology of sulpiride].

Authors:  C Laville
Journal:  Lille Med       Date:  1972-01

4.  Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.

Authors:  B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

5.  Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.

Authors:  C Köhler; S O Ogren; L Haglund; T Angeby
Journal:  Neurosci Lett       Date:  1979-06       Impact factor: 3.046

6.  On the use of lesions of afferents to localize neurotransmitter receptor sites in the striatum.

Authors:  T Hattori; H C Fibiger
Journal:  Brain Res       Date:  1982-04-22       Impact factor: 3.252

7.  Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro.

Authors:  K Starke; W Reimann; A Zumstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

8.  Rat climbing behavior elicited by stimulation of cerebral dopamine receptors.

Authors:  P Protais; J J Bonnet; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

9.  Stereoselectivity of presynaptic autoreceptors modulating dopamine release.

Authors:  S Arbilla; S Z Langer
Journal:  Eur J Pharmacol       Date:  1981-12-17       Impact factor: 4.432

10.  The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization.

Authors:  M Munemura; T E Cote; K Tsuruta; R L Eskay; J W Kebabian
Journal:  Endocrinology       Date:  1980-12       Impact factor: 4.736

View more
  12 in total

1.  Heterogeneity of D2 dopamine receptors in different brain regions.

Authors:  M N Leonard; C A Macey; P G Strange
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

2.  Rat climbing behavior elicited by stimulation of cerebral dopamine receptors.

Authors:  P Protais; J J Bonnet; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

3.  Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.

Authors:  H B Niznik; D E Grigoriadis; I Pri-Bar; O Buchman; P Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

4.  Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice.

Authors:  M Vasse; P Protais; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

5.  Effects of discriminant and non-discriminant dopamine antagonists on in vivo accumulation of 3H-N-propyl-norapomorphine in mouse striatum and tuberculum olfactorium.

Authors:  C Gulat-Marnay; A Lafitte; J C Schwartz; P Protais
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

6.  Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotides.

Authors:  M P Martres; P Sokoloff; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

7.  Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands.

Authors:  S Urwyler; D Coward
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-02       Impact factor: 3.000

8.  Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.

Authors:  D Lévesque; J Diaz; C Pilon; M P Martres; B Giros; E Souil; D Schott; J L Morgat; J C Schwartz; P Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

9.  3H-(-)DO 710 discriminates guanine nucleotide sensitive and insensitive dopamine binding sites.

Authors:  P Sokoloff; K Redouane; M Brann; M P Martres; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

10.  3H-Dopamine binding sites differ in rat striatum and pituitary.

Authors:  P Sokoloff; M P Martres; M Delandre; K Redouane; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.